Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Quadruple-Masked, Active-Controlled Phase 2b Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of VIS-101 Intravitreal Injection in Treatment- Naïve Participants With Neovascular Age-Related Macular Degeneration

NCT07798375 is registered in ClinicalTrials.gov with Everest Medicines (China) Co.,Ltd. as lead sponsor.

NCT NCT07798375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07798375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Quadruple-Masked, Active-Controlled Phase 2b Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of VIS-101 Intravitreal Injection in Treatment- Naïve Participants With Neovascular Age-Related Macular Degeneration
Lead sponsor
Everest Medicines (China) Co.,Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2028
Enrollment
244 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age related macular degeneration(namd)